# TGRX-326

Source: https://onco.cc/drugs/tgrx-326/  
OnCo record `tgrx-326` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TGRX-326 is an experimental small-molecule drug from Shenzhen TargetRx in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.

## Summary

TGRX-326 is a small-molecule drug developed by Shenzhen TargetRx. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06082635 (TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)), in non-small-cell lung cancer. The largest, NCT06082635, plans to enrol 321 participants (actual) with primary completion was scheduled for 2026-04-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: TGRX-326 QD (once a day)
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of TGRX-326: https://clinicaltrials.gov/search?intr=TGRX-326
- Sponsor page: https://www.tjrbiosciences.com

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Shenzhen TargetRx](https://onco.cc/companies/shenzhen-targetrx/)
- trials: [TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct05955391/), [TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nsclc-3/)

---
JSON: https://onco.cc/api/v1/entities/tgrx-326.json